Clinical trial
Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not…
NCT00104871 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00104871 |
|---|---|
| Title | Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy |
| Official title | A Phase II Study of Bortezomib in Metastatic Papillary Thyroid Carcinoma or Follicular Thyroid Carcinoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer |
| Intervention type | Drug |
| Interventions | Bortezomib |
| Enrollment | 24 |
| Start date | Dec 1, 2004 |
| Primary completion | May 1, 2010 |
| Completion | Apr 1, 2014 |
| First posted | Mar 4, 2005 |
| Last update posted | Dec 19, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: